Ilixadencel

N/A

Report date: 2026/01/31 20:00:09

Base Information

Drug NameIlixadencel
Drug Alias Name树突状细胞产品 - Immunicumllogeneic cancer vaccineDendritic cell vaccine - ImmunicumAllogeneic cancer vaccine - ImmunicumINTUVAX-HCC +[8] 
ClassificationVaccines > Development/production technology > Dendritic cell vaccineCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapy > Dendritic cell vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsCarcinoma, Renal CellCarcinoma, HepatocellularGastrointestinal Stromal Tumors
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaUnited StatesSweden +[9] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMendus AB
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMendus AB
Active IndicationsN/A
Inactive IndicationsCarcinoma, Renal CellCarcinoma, HepatocellularGastrointestinal Stromal Tumors

Other Information

ATC CodeN/A
Related LinksN/A